Department of Medical Pharmacology and Toxicology, Montpellier, University Hospital, Montpellier, France.
Department of Internal Medicine-Multi-Organic Diseases, Local Referral Center for Rare Auto-Immune Diseases, Saint Eloi Hospital, Montpellier University Hospital, Montpellier, France.
Cancer Immunol Immunother. 2022 Dec;71(12):3093-3097. doi: 10.1007/s00262-022-03208-2. Epub 2022 May 26.
Immune checkpoint inhibitors (ICI) restore immune response against cancer cells that can lead to immune-related adverse effects. While cardiovascular immune-related adverse effects are known to be associated with checkpoint inhibitors, recent case reports have raised concerns about the potential association with pulmonary hypertension (PH). By using the global pharmacovigilance database VigiBase, we investigated the onset of PH associated with ICI and propose a comprehensive description of the 42 cases of PH reported with ICI recorded in this database. Through this study and review of the cases published in the literature, we discuss the possible link between PH and ICI in the context of cancer in order to better understand this rare but potentially fatal event.
免疫检查点抑制剂 (ICI) 恢复了针对癌细胞的免疫反应，从而导致免疫相关不良反应。虽然心血管免疫相关不良反应与检查点抑制剂有关，但最近的病例报告引起了人们对其与肺动脉高压 (PH) 之间潜在关联的关注。通过使用全球药物警戒数据库 VigiBase，我们调查了与 ICI 相关的 PH 发病情况，并提出了该数据库中记录的 42 例与 ICI 相关的 PH 报告病例的综合描述。通过这项研究以及对文献中发表的病例的回顾，我们讨论了 PH 与癌症环境中的 ICI 之间的可能联系，以便更好地理解这种罕见但可能致命的事件。
